Site is Being Upgraded

Probiotic-based therapy for Squamous cell carcinoma of head and neck (HNSCC): Probiotic Lactobacillus Rhamnosus inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 16/November/2018, 12.03 am

Molecular therapy for Myocardial Infarction: Empagliflozin (trade name Jardiance), used in the treatment of TIIDM, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 15/November/2018, 11.48 pm
November 15, 2018
Lengthening the lifespan of mighty humans with a tiny Probiotic Lactobacillus reuteri GMNL-263: Probiotic Lactobacillus reuteri GMNL-263 may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others longevity-promoting genes, 16/November/2018, 11.34 pm
November 16, 2018
Show all

Introduction: What they say:

A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research Center, UCLA, Los Angeles, California, USA shows that inhibition of BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. This study was published, in the 9 March 2017 issue of the journal “Cancer Stem Cell” [the number 1 research journal in Stem cell Biology with an I.F of 22.387+], by Prof. Jiong Li, Chen D, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotic-based therapy for Squamous cell carcinoma of head and neck (HNSCC): Probiotic Lactobacillus Rhamnosus inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes


From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally; (ii) Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer globally;(iii) HNSCC is the third most common cancer in the developing world; (iv) each year nearly half a million people are diagnosed with HNSCC globally; (v) cancer deaths globally are expected to be doubled in a little more than a decades time; and (vi) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to activate cancer patients’ immune system against tumors (Cancer immunotherapy); (ii) anticancer drugs that target cancer stem cells (CSCs) that aid in tumor relapse, drug resistance and metastasis; (iii) a cheaper alternative to the existing expensive anticancer drugs; (iv) a side-effect-free natural product-based drug; (v) increase the therapeutic index of anti-cancer drugs; and (vi) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


What we infer from what they say:

Prof. Jiong Li’s research team has recently shown that: (1) cancer stem cells (CSCs) are enriched with oncoprotein BMI1 (B cell-specific Moloney murine leukemia virus integration site 1, which promote invasion and lymph node metastasis in HNSCC); (2) BMI1+ CSCs are resistant to anticancer drugs; and (3) BMI1+ CSCs contain increased AP-1 activity that promotes invasion, migration and metastasis of HNSCC. Further, they have shown that inhibition of AP-1 or BMI1: (a) increases chemosensitivity to drug-resistant tumors; (b) inhibits CSCs proliferation; (c) decreases tumor volume; (d) inhibits lymph node metastasis; and (e) eradicates HNSCC metastasis.


From research findings to therapeutic opportunity :

This study suggests, for the first time, a probiotic-based therapy for HNSCC. Probiotic Lactobacillus Rhamnosus, by increasing the expression of its target genes, it may decrease the expression of BMI1 and AP-1 expression (fig. 1). Thereby, it may: (i) overcome chemotherapeutic resistance; (ii) promote chemosensitivity; (iii) suppress cancer stem cells proliferation and regeneration in HNSCC; (iv) decrease tumor volume; (v) inhibit lymph node metastasis; (vi) inhibit invasion, migration, and metastasis. Thus, pharmacological formulations encompassing Probiotic Lactobacillus Rhamnosus, either alone or in combination with other anti-cancer drugs” may be used to inhibit the metastatic progression of HNSCC.Price 500 [easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how probiotic Lactobacillus Rhamnosus suppresses the expression of oncoproteins BMI-1 and AP-1 and promotes tumor regression.

Figure 1. Probiotic Lactobacillus Rhamnosus functions as an anticancer agent.


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How does Probiotic Lactobacillus Rhamnosus decrease the expression of oncoproteins BMI1 and AP-1 and inhibit lymph node metastasis in HNSCC?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Probiotic-based therapy for Squamous cell carcinoma of head and neck (HNSCC): Probiotic Lactobacillus Rhamnosus inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 16/November/2018, 12.02 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, Kindly drop us a line at admin@genomediscovery.org

Comments are closed.